• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Padraig McDonnell Assumes Agilent CEO Role

    5/1/24 8:45:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email

    Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company's CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent's history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501393789/en/

    Padraig McDonnell (Photo: Business Wire)

    Padraig McDonnell (Photo: Business Wire)

    "It's an incredible honor to serve as CEO of this great company that impacts the world by advancing the quality of life," McDonnell said. "I'm proud of how we forge partnerships with our customers to help them bring great science to life, and I'm excited to lead Agilent because of the possibilities that lie ahead for us."

    "Based on his proven record of success, we firmly believe Padraig McDonnell is the right choice to lead Agilent," said Koh Boon Hwee, chairman of Agilent's Board of Directors. "We look forward to working with him to build on that success as CEO."

    Before being named CEO-elect in February, McDonnell, 52, had served as president of the Agilent CrossLab Group (ACG) since May 2020. His role leading ACG expanded in November 2021, when he was also named to lead the company's commercial organization as chief commercial officer.

    As President of ACG, McDonnell drove outstanding growth in Agilent's services business, with significant improvements in profitability and customer satisfaction. As chief commercial officer, he also led the transformation of the customer experience at Agilent by improving the end-to-end customer journey and customer lifetime value.

    Prior to becoming ACG president, McDonnell was vice president and general manager of Agilent's Chemistries and Supplies Division, a role to which he was named in 2017. He has been in the analytical- and scientific-instrument industry for 26 years, starting his career with Agilent's predecessor Hewlett-Packard Co. in 1998.

    "With Padraig at the helm, the future is bright for Agilent," McMullen said. "His leadership skills, knowledge and customer focus will serve the company well for many years to come."

    For more information regarding Agilent's new CEO, please visit the Agilent website.

    About Agilent Technologies

    Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240501393789/en/

    Get the next $A alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    8/28/2024$157.00Overweight
    Wells Fargo
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/3/2024$135.00Hold
    Jefferies
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    12/13/2023$140.00Outperform
    Wolfe Research
    12/12/2023$130.00 → $133.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agilent upgraded by Barclays with a new price target

    Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously

    2/10/25 6:55:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wells Fargo initiated coverage on Agilent with a new price target

    Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00

    8/28/24 7:20:29 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Citigroup with a new price target

    Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously

    7/10/24 7:22:08 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent Announces Cash Dividend of 24.8 Cents per Share

    Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on Oct. 22, 2025, to all shareholders of record as of the close of business on Sept. 30, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide truste

    9/17/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Aquatech Acquires Koch's Direct Lithium Extraction Business, Integrating Li-Pro™ DLE into the PEARL™ Technology Platform

    CANONSBURG, Pa., Sept. 16, 2025 /PRNewswire/ -- Aquatech has acquired Koch Technology Solutions' (KTS) direct lithium extraction (DLE) business, integrating the Li-Pro™ Lithium Selective Sorption (LSS) technology and extensive Li-Pro IP portfolio into the PEARL™ process technology platform. The acquisition of KTS' Li-Pro LSS technology adds direct lithium extraction to Aquatech's extensive process flowsheet IP, lithium conversion and crystallization capabilities. With this addition, Aquatech's PEARL platform becomes the only commercially proven, end-to-end flowsheet solution f

    9/16/25 5:21:00 PM ET
    $A
    $EQNR
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Integrated oil Companies
    Energy

    Agilent to Participate in 2025 Bank of America Global Healthcare Conference

    Agilent Technologies Inc. (NYSE:A) today announced that President and CEO Padraig McDonnell will participate in a fireside chat at this year's Bank of America Global Healthcare Conference in London. The fireside chat will be at 9:50-10:30 a.m. British Summer Time (BST) on Sept. 25 in London. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software,

    9/11/25 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Mcdonnell Padraig sold $249,760 worth of shares (2,000 units at $124.88), decreasing direct ownership by 6% to 33,448 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/4/25 3:36:26 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Mcdonnell Padraig sold $226,900 worth of shares (2,000 units at $113.45), decreasing direct ownership by 5% to 35,448 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    8/4/25 4:15:32 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    V.P., Corporate Controller Gonsalves Rodney was granted 9,031 shares, increasing direct ownership by 41% to 30,972 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    7/18/25 2:43:11 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    SEC Filings

    View All

    SEC Form 10-Q filed by Agilent Technologies Inc.

    10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    8/29/25 4:33:55 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    8/27/25 4:06:24 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    8/8/25 4:15:28 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

    Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

    4/24/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Acquire North American CDMO BIOVECTRA

    Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

    7/22/24 9:01:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care

    $A
    Financials

    Live finance-specific insights

    View All

    Agilent Announces Cash Dividend of 24.8 Cents per Share

    Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on Oct. 22, 2025, to all shareholders of record as of the close of business on Sept. 30, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide truste

    9/17/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Aquatech Acquires Koch's Direct Lithium Extraction Business, Integrating Li-Pro™ DLE into the PEARL™ Technology Platform

    CANONSBURG, Pa., Sept. 16, 2025 /PRNewswire/ -- Aquatech has acquired Koch Technology Solutions' (KTS) direct lithium extraction (DLE) business, integrating the Li-Pro™ Lithium Selective Sorption (LSS) technology and extensive Li-Pro IP portfolio into the PEARL™ process technology platform. The acquisition of KTS' Li-Pro LSS technology adds direct lithium extraction to Aquatech's extensive process flowsheet IP, lithium conversion and crystallization capabilities. With this addition, Aquatech's PEARL platform becomes the only commercially proven, end-to-end flowsheet solution f

    9/16/25 5:21:00 PM ET
    $A
    $EQNR
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Integrated oil Companies
    Energy

    Agilent Reports Third-Quarter Fiscal Year 2025 Financial Results

    Agilent delivers strong revenue growth, raises growth outlook  Highlights Revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% on a core(1) basis compared with the third quarter of 2024. GAAP net income of $336 million; earnings per share (EPS) of $1.18, up 22% from the third quarter of 2024. Non-GAAP(2) net income of $390 million; EPS of $1.37, up 4% from the third quarter of 2024. These results reflect a full quarter of the dynamic tariff environment. Outlook for full 2025 fiscal year and Q4 Full-year revenue outlook revised at a range of $6.91 billion to $6.93 billion, repr

    8/27/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials